Evaluation of Novel Therapies Using Spontaneous Seizure Models

Watch Now

Sponsored by:

ADInstruments
Date:
October 4, 2023
Time (PT):
2:00 PM
Duration (min):
60

In this webinar, Dr. Cameron Metcalf covers the technical requirements and benefits of spontaneous seizure models, addressing the challenges and optimization of 24/7 video-EEG data collection for epilepsy therapy development.

In the Anticonvulsant Drug Development (ADD) Program, novel compounds are evaluated using a battery of epilepsy models. While traditional drug screening efforts have centered around single administration in evoked seizure models, there has been an increase in efforts toward more etiologically relevant spontaneous seizure models. These efforts require 24/7 video-EEG systems capable of recording multiple animals simultaneously. Further, as the Contract Site for the Epilepsy Therapy Screening Program of the NINDS, screening studies are performed using established and validated approaches that require larger group sizes to achieve statistical power for the endpoints.

As such, efforts to screen compounds have required multiple video-EEG recording units using tethered and radio-telemetry systems. The ADD Program has implemented several models with spontaneous seizures and validated these models by screening FDA-approved antiseizure drugs. Novel compounds can then be evaluated and compared to established drugs as part of a preclinical profiling strategy. Studies are completed in a blinded manner, including blinded video-EEG review.

Presenters

Cameron Metcalf

University of Utah (ADD Program)
Associate Director

Cameron S. Metcalf, PhD is a Research Assistant Professor of Pharmacology & Toxicology and the Associate Director of the Anticonvulsant Drug Development Program at the University of Utah. He has extensive experience in preclinical models of epilepsy and other neurologic conditions.

Read More

Katrina Irey

ADInstruments, Inc. (North American Sales)
Kaha Sales Specialist

Katrina Irey began working for ADInstruments in 2018 and has truly loved learning about the complexities of all the research projects that her customers have been involved with. It is Katrina's passion to help customers find solutions to their unique research questions and to ensure they are successfully recording high quality data to support their findings.

Read More

Sponsor

ADInstruments

Established in 1988, ADInstruments develops high performance digital data acquisition and analysis solutions for biomedical research and life science education.

Content Partners

American Physiological Society

Physiology is a broad area of scientific inquiry that focuses on the biological function of living organisms. Today, physiology could not be more important. In fact, physiology is essential to answering virtually every critical question facing us in our understanding of life, health and disease.

About APS

Mission: To advance scientific discovery, understand life, and improve health. Vision: A global multidisciplinary community of scientists solving the major problems affecting life and health. Founded in 1887, the American Physiological Society is a global leader in expanding knowledge related to biological function. We connect a multidisciplinary community of nearly 10,000 scientists and educators from around the world, driving collaboration and spotlighting scientific discoveries in physiology and related disciplines. Our members are advancing treatments and cures for everything from cancer and heart disease, to obesity and addiction. They are also deepening our insight into living organisms generally, helping us to better understand how things like climate change are affecting the world around us. The Society serves this dynamic community in many ways, including:

Society for Neuroscience

The Society for Neuroscience is the world’s largest organization of scientists and physicians devoted to understanding the brain and the nervous system. Founded in 1969, the Society for Neuroscience (SfN) now has nearly 35,000 members in more than 95 countries. Year-round programming includes the publishing of two highly regarded scientific journals, JNeurosci and eNeuro; professional development resources and career training through Neuronline, the Society’s home for learning and discussion; science advocacy and public policy engagement including annual Capitol Hill Day; and a variety of engaging public outreach efforts, led by the expanding and interactive collection of public-facing resources on BrainFacts.org. Approximately 100 staff committed to SfN’s mission are employed at its headquarters building in downtown Washington, D.C., which the Society has owned since 2006. SfN’s annual meeting regularly attracts more than 30,000 attendees, representing 80 countries; 536 exhibiting companies; and close to 300 journalists. SfN exists to:
  • Advance scientific exchange;
  • Support the neuroscience community;
  • Educate and engage the public; and
  • Advocate for the field.

Federation of European Neuroscience Societies

Federation of European Neuroscience Societies (FENS) is the voice of European neuroscience.

Founded in 1998 at the first Forum of European Neuroscience, the FENS is the main organization for neuroscience in Europe. FENS currently represents 44 national and single-discipline neuroscience societies across 33 European countries and more than 22,000 member scientists.

FENS promotes neuroscience research to policy-makers, funding bodies and the general public, both regionally and internationally. FENS promotes excellence in neuroscience research and facilitates exchanges and networking between neuroscientists within the European Research Area and beyond. FENS was created to bring together the scientific community and advance research and education in neuroscience in Europe and beyond.

FENS believes in inclusive, responsible science. FENS takes great pride in its position as the voice of European neuroscience and strives to structure its activities around the following principles.

American Autonomic Society

The American Autonomic Society (AAS) has been established to bring together individuals from diverse disciplines who share an interest in the structure and function of the autonomic nervous system and in the pathology, treatment, and prevention of its disorders. The Society sponsors annual meetings and provides a point of contact among the many interested clinical and basic scientists who wish to communicate across disciplinary lines.

The AAS began informally in 1990 at Vanderbilt University in Nashville, Tennessee. Important motivating force for the initial meeting were Dr. David Robertson and Ms. Dorothy Trainor-Kingsbury (Shy-Drager Support Group). The Society was formally established in 1992, and Dr. Robertson became its first president. The broad aim of the AAS is to provide a vehicle for investigators and clinicians interested in the autonomic nervous system to interact. It aims to promote research, education, and the academic practice in the autonomic disorders. The Society has escalated in its membership, successfully obtained tax-exempt status, adopted a formal charter, and has its own journal (Clinical Autonomic Research).

The Society has an American infrastructure but a strongly international character. Its membership is open to persons of all countries who share the same interests. During the past quarter century, the AAS has expanded from less than 50 members in 1992 to over 150 members today, focusing on both clinical and basic science, and has taken on a new role in the education of physicians in autonomic disorders. The collegial atmosphere and ongoing collaborative efforts has sparked several important discoveries that directly impact the lives of people with autonomic disorders. Partnerships with support groups have expanded the reach of the AAS into the public eye, while partnerships with industry have culminated in approval of new therapies for people with autonomic disorders.

Scientist.com

Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.

We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.

Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.

Related Content

Related Content